Inside Health Policy | Lawyer: FDA Proposal to Restrict Flavored ENDS Sales May Violate TCA

Marc Scheineson comments on the Food and Drug Administration review of Phillip Morris’ modified risk tobacco product application for iQOS.

Marc Scheineson is quoted on the Food and Drug Administration’s expected approach to regulating CBD.

Alston & Bird has expanded its health care and life sciences regulatory and compliance capabilities with the addition of counsel Alexandra Marzelli, former associate chief counsel at the U.S. Food and Drug Administration (FDA). Based in the firm’s Washington, D.C. office, Marzelli joins Alston & Bird’s Health Care and FDA/Food, Drug & Device Groups, where she will advise clients on the FDA’s complex approval process and regulatory compliance for prescription and over-the-counter drugs, biologics, medical devices, food ingredients, and other products regulated by the agency.

Marc Scheineson is quoted on the U.S. Food and Drug Administration’s cannabidiol policies and safety regulations.

Marc Scheineson is quoted on Janet Woodcock’s proposed nomination as the permanent commissioner of the U.S. Food and Drug Administration.